Prognostic significance of Notch ligands in patients with non‑small cell lung cancer

Pancewicz‑Wojtkiewicz,Joanna; Eljaszewicz,Andrzej; Kowalczuk,Oksana; Niklinska,Wieslawa; Charkiewicz,Radoslaw; Kozłowski,Miroslaw; Miasko,Agnieszka; Moniuszko,Marcin

doi:10.3892/ol.2016.5420

Prognostic significance of Notch ligands in patients with non‑small cell lung cancer

Authors:
- Joanna Pancewicz‑Wojtkiewicz
- Andrzej Eljaszewicz
- Oksana Kowalczuk
- Wieslawa Niklinska
- Radoslaw Charkiewicz
- Miroslaw Kozłowski
- Agnieszka Miasko
- Marcin Moniuszko
View Affiliations

Affiliations: Department of Histology and Embryology, Medical University of Bialystok, 15‑269 Bialystok, Poland, Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, 15‑269 Bialystok, Poland, Department of Clinical Molecular Biology, Medical University of Bialystok, 15‑269 Bialystok, Poland, Department of Thoracic Surgery, Medical University of Bialystok, 15‑269 Bialystok, Poland
Published online on: November 23, 2016 https://doi.org/10.3892/ol.2016.5420
Pages: 506-510

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Notch signaling pathway is deregulated in numerous solid types of cancer including non-small cell lung cancer (NSCLC). However, the profile of Notch ligand expression remains unclear. Therefore, the present study aimed to determine the profile of Notch ligands in NSCLC patients and to investigate whether quantitative assessment of Notch ligand expression may have prognostic significance in NSCLC patients. The study was performed in 61 pairs of tumor and matched unaffected lung tissue specimens obtained from patients with various stages of NSCLC, which were analyzed by reverse transcription‑polymerase chain reaction. The marked expression levels of certain analyzed genes were detected in NSCLC samples and in noncancerous lung samples. Of the five Notch ligands, jagged 1 (Jag1), jagged 2, delta‑like protein 1 and delta‑like protein 4 were expressed in the majority of tissues, but their expression levels were reduced in NSCLC when compared with noncancerous lung tissue (P<0.001). Delta‑like protein 3 expression was consistently low and was observed only in 21/61 tumor tissue samples. Taken together, Notch ligands are expressed in NSCLC. However, the expression level is reduced when compared to noncancerous tissue. Furthermore, the present study revealed that quantitative assessment of Jag1 expression in NSCLC may improve prognostication of patient survival.

View Figures

View References

1	Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
3	Greenhalgh J, Dwan K, Boland A, Bates V, Vecchio F, Dundar Y, Jain P and Green JA: First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer. Cochrane Database Syst Rev CD010383. 2016. View Article : Google Scholar
4	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar : PubMed/NCBI
5	Kosakowska EA, Stec R, Charkiewicz R, Skoczek M and Chyczewski L: Molecular differences in the KRAS gene mutation between a primary tumor and related metastatic sites-case report and a literature review. Folia Histochem Cytobiol. 48:597–602. 2010.PubMed/NCBI
6	Ludwig JA and Weinstein JN: Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 5:845–856. 2005. View Article : Google Scholar : PubMed/NCBI
7	Radtke F and Raj K: The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer. 3:756–767. 2003. View Article : Google Scholar : PubMed/NCBI
8	Sethi N and Kang Y: Notch signalling in cancer progression and bone metastasis. Br J Cancer. 105:1805–1810. 2011. View Article : Google Scholar : PubMed/NCBI
9	Pancewicz J and Nicot C: Current views on the role of Notch signaling and the pathogenesis of human leukemia. BMC Cancer. 11:5022011. View Article : Google Scholar : PubMed/NCBI
10	Aster JC, Pear WS and Blacklow SC: The Varied Roles of Notch in Cancer. Annual Review of Pathology: Mechanisms of Disease. 12:null. 2017. View Article : Google Scholar
11	D'Souza B, Miyamoto A and Weinmaster G: The many facets of Notch ligands. Oncogene. 27:5148–5167. 2008. View Article : Google Scholar : PubMed/NCBI
12	Shimizu K, Chiba S, Kumano K, Hosoya N, Takahashi T, Kanda Y, Hamada Y, Yazaki Y and Hirai H: Mouse jagged1 physically interacts with notch2 and other notch receptors. Assessment by quantitative methods. J Biol Chem. 274:32961–32969. 1999. View Article : Google Scholar : PubMed/NCBI
13	Xu K, Moghal N and Egan SE: Notch signaling in lung development and disease. Adv Exp Med Biol. 727:89–98. 2012. View Article : Google Scholar : PubMed/NCBI
14	Li D, Masiero M, Banham AH and Harris AL: The notch ligand JAGGED1 as a target for anti-tumor therapy. Front Oncol. 4:2542014. View Article : Google Scholar : PubMed/NCBI
15	Nasarre P, Potiron V, Drabkin H and Roche J: Guidance molecules in lung cancer. Cell Adh Migr. 4:130–145. 2010. View Article : Google Scholar : PubMed/NCBI
16	Jin MM, Ye YZ, Qian ZD and Zhang YB: Notch signaling molecules as prognostic biomarkers for non-small cell lung cancer. Oncol Lett. 10:3252–3260. 2015.PubMed/NCBI
17	Choi K, Ahn YH, Gibbons DL, Tran HT, Creighton CJ, Girard L, Minna JD, Qin FX and Kurie JM: Distinct biological roles for the notch ligands Jagged-1 and Jagged-2. J Biol Chem. 284:17766–17774. 2009. View Article : Google Scholar : PubMed/NCBI
18	Endoh H, Tomida S, Yatabe Y, Konishi H, Osada H, Tajima K, Kuwano H, Takahashi T and Mitsudomi T: Prognostic model of pulmonary adenocarcinoma by expression profiling of eight genes as determined by quantitative real-time reverse transcriptase polymerase chain reaction. J Clin Oncol. 22:811–819. 2004. View Article : Google Scholar : PubMed/NCBI
19	Bolkun L, Grubczak K, Schneider G, Zembko P, Radzikowska U, Singh P, Kloczko J, Ratafczak MZ, Moniuszko M and Eljaszewicz A: Involvement of BAFF and APRIL in resistance to apoptosis of acute myeloid leukemia. J Cancer. 7:1979–1983. 2016. View Article : Google Scholar : PubMed/NCBI
20	Yuan X, Wu H, Xu H, et al: Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. Sci Rep. 5:103382015. View Article : Google Scholar : PubMed/NCBI
21	Li C, Song G, Zhang S, Wang E and Cui Z: Wnt3a increases the metastatic potential of non-small cell lung cancer cells in vitro in part via its upregulation of Notch3. Oncol Rep. 33:1207–1214. 2015.PubMed/NCBI
22	Nguyen D, Rubinstein L, Takebe N, Miele L, Tomaszewski JE, Ivy P, Doroshow JH and Yang SX: Notch1 phenotype and clinical stage progression in non-small cell lung cancer. J Hematol Oncol. 8:92015. View Article : Google Scholar : PubMed/NCBI
23	Leong KG and Karsan A: Recent insights into the role of Notch signaling in tumorigenesis. Blood. 107:2223–2233. 2006. View Article : Google Scholar : PubMed/NCBI
24	Jonusiene V, Sasnauskiene A, Lachej N, Kanopiene D, Dabkeviciene D, Sasnauskiene S, Kazbariene B and Didziapetriene J: Down-regulated expression of Notch signaling molecules in human endometrial cancer. Med Oncol. 30:4382013. View Article : Google Scholar : PubMed/NCBI